Flexipharm Austrading announces product update on Arsenic Trioxide Phebra

Extension to in-use stability time

FARNBOROUGH, England, [23] March, 2020: Flexipharm Austrading, the UK specialty pharmaceutical
company focused on supplying the NHS with Better, Critical Care Medicines, today announced an
important improvement to the ‘Summary of Product Characteristics’ for its differentiated arsenic
trioxide injection product, Arsenic Trioxide Phebra (1mg/ml concentrate for solution for infusion).

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...